Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Inavolisib in combination with Bevacizumab and FOLFOX or FOLFIRI as first-line therapy in colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Inavolisib (Inavolisib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Colorectal Cancer | Phase 2 | Status: WITHDRAWN